Get the Stockscreener App
0.4015
10.00%
0.0365
Pre-market:
.39
-0.0115
-2.86%
Lunai Bioworks Inc stock is traded at $0.4015, with a volume of 1.30M.
It is up +10.00% in the last 24 hours and down -5.62% over the past month.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
See More
Previous Close:
$0.365
Open:
$0.3791
24h Volume:
1.30M
Relative Volume:
0.12
Market Cap:
$9.71M
Revenue:
-
Net Income/Loss:
$-125.52M
P/E Ratio:
-0.0532
EPS:
-7.5468
Net Cash Flow:
$-5.72M
1W Performance:
-0.10%
1M Performance:
-5.62%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.3527
$0.4015
1-Week Range:
$0.35
$0.60
52-Week Range:
$0.1513
$1.66
Lunai Bioworks Inc Stock (LNAI) Company Profile
Name
Lunai Bioworks Inc
Sector
Industry
Phone
45 39179840
Address
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare LNAI vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
0.4015 | 8.83M | 0 | -125.52M | -5.72M | -7.5468 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Lunai Bioworks Inc Stock (LNAI) Latest News
If You Invested $1,000 in Renovaro (RENB) - Stock Titan
$400M to $1.2 Billion US Countermeasures Program Presents Huge Opportunity for New AI Platform to Meet Emerging Battlefield and Terrorism Threats: Lunai Bioworks (Nasdaq: LNAI) - Barchart.com
$400M to $1.2 Billion US Countermeasures Program Presents Huge - openPR.com
Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI) - PRLog
Lunai Bioworks Engages Initial U.S. Countermeasure Opportunities Following $400M–$1.2B Consortium Launch - weeklyvoice.com
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model - Finviz
LNAI Initiates Consortium to Speed Up Chemical Countermeasure De - GuruFocus
Lunai Bioworks (LNAI) Stock Forecast and Price Target 2026 $LNAI - MarketBeat
LNAI stock: Lunai Bioworks (NASDAQ) $0.52, vol 509,735,274 on 17 Mar 2026: monitor AI oncology signals - Meyka
Why Is This Micro-Cap Biotech Stock Up 150% Today? - Stocktwits
Best Manufacturing Stocks To Watch TodayMarch 17th - MarketBeat
Why Is LNAI Stock Skyrocketing Today? - Stocktwits
Top Biotech Stocks To Follow TodayMarch 17th - MarketBeat
Lunai Bioworks (LNAI) jumps 189% as traders refocus on recent IP update and looming Nasdaq listing decision - Quiver Quantitative
Lunai Launches AI Safeguard Sentinel to Prevent Chemical Agent Generation - Intellectia AI
ENOB FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important September 26 Deadline in Securities Class ActionENOB - marketscreener.com
Lunai Bioworks initiates employee furloughs and salary deferrals to preserve liquidity - Investing.com UK
Lunai Bioworks Furloughs Staff Amid Liquidity Constraints - TipRanks
Lunai Bioworks implements temporary furlough of employees in US and CanadaSEC filing - marketscreener.com
Lunai Bioworks implements temporary furloughs, execs defer salaries to preserve liquidity - TradingView
Form 8K Lunai Bioworks Inc For: 5 March By Investing.com - Investing.com Canada
Financial Survey: Lunai Bioworks (NASDAQ:LNAI) versus Lite Strategy (NASDAQ:LITS) - Defense World
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery - The Sheboygan Press
Lunai Bioworks Highlights Sentinel AI Safeguard After Anthropic CEO Warning on AI Chemical and Biological Threats - The Destin Log
LNAI Should I Buy - Intellectia AI
Lunai Bioworks Faces Nasdaq Delisting, Hearing Scheduled - TipRanks
Lunai Bioworks Received Notice of Delisting - TradingView
Head-To-Head Comparison: Lunai Bioworks (NASDAQ:LNAI) vs. NexImmune (OTCMKTS:NEXI) - Defense World
LNAI | Lunai Bioworks Inc. Common Institutional Ownership - Quiver Quantitative
LNAI | Lunai Bioworks Inc. Common Insider Trading - Quiver Quantitative
Lunai Bioworks Reports Q2 Loss - National Today
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping - Finviz
Lunai Bioworks kicks off AI-driven oncology pilot to analyze phase 2 colorectal cancer trial - MSN
Lunai Bioworks: Second Quarter Financial Results Overview - Bitget
Lunai Bioworks: Fiscal Q2 Earnings Snapshot - marketscreener.com
Lunai Bioworks Inc. SEC 10-Q Report - TradingView
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC - Finviz
Lunai Bioworks Faces Nasdaq Delisting After Bid Price Breach - TipRanks
Lunai Bioworks Launches AI Oncology Pilot to Analyze Phase 2 Colorectal Cancer Trial Data - AIM Media House
Lunai Bioworks Updates Shareholders on February 2026 Operational Progress and Future Plans - geneonline.com
Lunai Bioworks, Inc. Issues Letter to Shareholders - The Malaysian Reserve
LNAI Partners on Phase 2 Cancer Trial to Enhance Patient Outcomes - GuruFocus
LNAI Strengthens AI Platform for Biotech Innovations and Partner - GuruFocus
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - Finviz
Lunai Bioworks (Nasdaq LNAI) launches AI oncology pilot - marketscreener.com
Lunai Bioworks (Nasdaq Lnai) Launches Ai Oncology Pilot - TradingView
Lunai Bioworks launches AI analysis of colorectal cancer trial data - Investing.com
Lunai Bioworks Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - marketscreener.com
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons - Finviz
Lunai Launches Sentinel AI Biosecurity Layer - Intellectia AI
Lunai Bioworks Inc Stock (LNAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):